AVANIR pharmaceuticals entered into a lucrative global research, development and commercialization agreement with Novartis to develop orally active small molecule therapeutics targeting macrophage migration inhibitory factor (MIF) for treating inflammatory diseases. The deal is worth up to US$200 M.